1197-37-1

Basic information

• Product Name: 4-ETHOXYBENZENE-1,2-DIAMINE
• Synonyms: 4-ETHOXYBENZENE-1,2-DIAMINE;4-Ethoxyl-o-phenylenediamine;(2-amino-5-ethoxy-phenyl)amine;1,2-DiaMino-4-ethoxybenzene[3,4-diaMinophenol ethyl ether];1,2-Benzenediamine, 4-ethoxy-
• CAS NO: 1197-37-1
• Molecular Formula: C₈H₁₂N₂O
• Molecular Weight: 152.19
• EINECS: 214-825-0
• Product Categories: Others chemical reagents
• Mol File: 1197-37-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 79-81℃
• Boiling Point: 274.67°C (rough estimate)
• Flash Point: 163.802 °C
• Appearance: /
• Density: 1.131±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.00157mmHg at 25°C
• Refractive Index: 1.4940 (estimate)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 4.82±0.10(Predicted)
• CAS DataBase Reference: 4-ETHOXYBENZENE-1,2-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ETHOXYBENZENE-1,2-DIAMINE(1197-37-1)
• EPA Substance Registry System: 4-ETHOXYBENZENE-1,2-DIAMINE(1197-37-1)

Safety Data

• Hazardous Substances Data: 1197-37-1(Hazardous Substances Data)

Usage

General Description

4-Ethoxybenzene-1,2-diamine, also known as N,N'-bis (2-aminoethyl) aniline or 1,2-benzenediamine, 4-ethoxy-, is a chemical compound with the molecular formula C10H14N2O. This organic substance belongs to the family of Aniline and Substituted Anilines. Common characteristics of this family include a benzene ring connected to an amino group (NH2). It often appears as a slightly yellowish liquid. Little is known about this chemical's applications or potential health effects, and it is not widely used or produced commercially. This substance could present hazards if improperly handled, as is generally true for many chemicals. Therefore, appropriate safety measures should be taken while handling it. It may be harmful if swallowed, inhaled, or comes into contact with skin.

InChI:InChI=1/C8H12N2O/c1-2-11-6-3-4-7(9)8(10)5-6/h3-5H,2,9-10H2,1H3

Upstream product

• 7647-01-0 hydrogenchloride 
• 89770-34-3 6-ethoxyquinoxaline 
• 1753-21-5 5-Ethoxy-2,1,3-benzothiadiazole 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 27076-16-0 5-ethoxy-2-nitroaniline 
• 62-44-2 4-ethoxyacetanilide 
• 885-81-4 N-(4-ethoxy-2-nitrophenyl)acetamide 
• 64-17-5 ethanol 
• 616-86-4 2-nitro-4-ethoxyaniline 
• 873967-25-0 N,N'-(4-ethoxy-o-phenylene)-bis-acetamide 
• 67169-91-9 N-(2-amino-4-ethoxyphenyl)acetamide 

Downstream Products

• 39513-22-9 5-Ethoxy-2-benzimidazolinon 
• 283612-27-1 5-ethoxy-2-isobutyl-1(3)H-benzimidazole 
• 117836-57-4 1-(4-nitrophenyl)-2-phenyl-5-ethoxy-1,1a-dihydro/1,2-a/quinoxaline 
• 111337-04-3 2,4-Bis-(4-chloro-phenyl)-8-ethoxy-2-methyl-2,3-dihydro-1H-benzo[b][1,4]diazepine 
• 111337-05-4 8-Ethoxy-2-methyl-2,4-bis-(4-nitro-phenyl)-2,3-dihydro-1H-benzo[b][1,4]diazepine 
• 55489-15-1 5-ethoxy-1,3-dihydro-2H-benzo[d]imidazole-2-thione 
• 651768-93-3 ethyl 5-[N-(2-amino-4-ethoxyphenyl)amino]-1,2,3-thiadiazole-4-carboxylate 
• 3925-93-7 2-phenyl-5⁽⁶⁾-hydroxybenzimidazole 
• 540515-45-5 1-(6-ethoxy-1H-benzimidazol-2-yl)ethanol 
• 55489-15-1 2-mercapto-5-ethoxybenzimidazole 
• 1351161-56-2 C₂₅H₂₆F₂N₂O₄ 
• 1351161-57-3 C₂₅H₂₆F₂N₂O₄ 
• 1351159-55-1 2-{[4-(2,5-difluorobenzyloxy)phenyl]ethoxymethyl}-5-ethoxy-1H-benzimidazole 
• 768-10-5 benzo[1,2,5]thiadiazol-5-ol 

Relevant articles and documents

Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization

PRMT5 plays important roles in diverse cellular processes and is upregulated in several human malignancies. Besides, PRMT5 has been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments, with a Kd of 0.987 μM. Kinetic experiments indicated that 17 was a SAM competitive inhibitor other than the substrate. In addition, 17 showed selective antiproliferative effects against MV4-11 cells, and further studies indicated that the mechanism of cellular antitumor activity was due to the inhibition of PRMT5 mediated SmD3 methylation. 17 may represent a promising lead compound to understand more about PRMT5 and potentially assist the development of treatments for leukemia indications.

HETEROCYCLIC ACETAMIDE COMPOUND

[Problem] A compound which is useful as a dopamine D1 receptor positive allosteric modulator (D1 PAM) is provided. [Means for Solution] The present inventors have studied a compound which has a dopamine D1 receptor positive allosteric modulating activity and is useful as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like, and they have thus found that a heterocyclic acetamide compound has a dopamine D1 receptor positive allosteric modulating activity, thereby completing the present invention. The heterocyclic acetamide compound of the present invention has a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.

Reaction of 5-halo-1,2,3-thiadiazoles with aliphatic diamines. Synthesis and intramolecular cyclization of bis(1,2,3-triazolyl-1,2,3-thiadiazolyl)sulfides

Bis[1,2,3]triazolo[1,5-f:5′,1′-b][1,3,6]thiadiazepine and [1,5-g:5′,1′-b][1,3,7]thiadiazocine ring systems have been synthesized from 5-halo-1,2,3-thiadiazoles and aliphatic diamines. We have found that the last step of the process is the cyclization of initially formed bis(1,2,3-triazolyl-1,2,3-thiadiazolyl)sulfides. The structures of the intermediates and products were supported by different NMR spectroscopic methods (1H coupled 13C NMR, 2D HETCOR, HMBC and 1D INADEQUATE experiments) and mass spectrometry. Differences in the reaction pathway for aliphatic and less nucleophilic aromatic diamines were determined.